Bridgebio Pharma shares rise 1.97% premarket after novel human genetics evidence confirms estimates of genetic prevalence and underdiagnosis of ADH1.

Bridgebio Pharma, Inc. rose 1.97% in premarket trading. The company's stock price increased following the release of two news articles highlighting novel human genetics evidence that confirms estimates of genetic prevalence, underdiagnosis, and potentially greater symptom burden of gain-of-function CASR variants associated with ADH1. This news is positive for the company as it validates their research and could lead to increased recognition and treatment of the disease.